Related coverage linked through entity extraction aliases.
Feb 16, 2026
Compass Pathways' COMP360 synthetic psilocybin met primary endpoints in Phase 3 trials for treatment-resistant depression, with the company planning to submit a new drug application in Q4 2026.
Feb 14, 2026
Disc Medicine received a complete response letter from the FDA for bitopertin as a treatment for erythropoietic protoporphyria. The FDA acknowledged the drug lowers PPIX levels but requires evidence from the ongoing Phase 3 APOLLO study before approval.
Feb 13, 2026
Aethlon Medical reported Q3 2026 financial results with a $2.06 million operating loss while advancing its Australian oncology trial of the Hemopurifier device. The company achieved 27% year-to-date cost reductions and targets a late March safety review.
